Further drug development was discontinued, with Boehringer Ingelheim pursuing other obesity drugs, while the global rights to the amylin analogue program remained with Zealand Pharma.207, 208, 209. The gene discussed is IAPP; the disease is obesity due to melanocortin 4 receptor deficiency.